Most Recent

image: Are Cancer Stem Cells Ready for Prime Time?

Are Cancer Stem Cells Ready for Prime Time?

By | April 1, 2012

A flood of new discoveries has refined our definition of cancer stem cells. Now it’s up to human clinical trials to test if they can make a difference in patients.

48 Comments

image: Deliberating Over Danger

Deliberating Over Danger

By | April 1, 2012

The creation of H5N1 bird flu strains that are transmissible between mammals has thrown the scientific community into a heated debate about whether such research should be allowed and how it should be regulated.

16 Comments

image: Speaking of Science

Speaking of Science

By | April 1, 2012

April 2012's selection of notable quotes

2 Comments

image: The Best of Both Worlds

The Best of Both Worlds

By | April 1, 2012

Choosing to work in industry does not preclude a return to academe. But the move back takes some planning and finesse.

3 Comments

image: Failed Drugs Expose Preclinical Blunders

Failed Drugs Expose Preclinical Blunders

By | March 30, 2012

Once a promising cancer treatment, the failure of PARP inhibitors in the clinic may be due to flawed preclinical studies.

2 Comments

image: More Scrutiny for Senior Scientists?

More Scrutiny for Senior Scientists?

By | March 30, 2012

The NIH plans an extra layer of review for scientists with at least $1.5 million in existing grants.

2 Comments

image: Courts Re-Examining Gene Patents

Courts Re-Examining Gene Patents

By | March 28, 2012

The US Supreme Court ordered patents held by Myriad Genetics to be reviewed further by the Federal Circuit Court.

2 Comments

image: MIT Students Petition Congress

MIT Students Petition Congress

By | March 27, 2012

Graduate students ask for more federal research support.

2 Comments

image: Mouse Made For You

Mouse Made For You

By | March 23, 2012

Mice “avatars” grafted with patient tumor tissue help identify effective drug regimens.

4 Comments

image: Pharma Puts Up Money for Biotech

Pharma Puts Up Money for Biotech

By | March 21, 2012

GlaxoSmithKline and Johnson & Johnson contribute a total of $100 million to early-stage biotech endeavors.

0 Comments

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Mettler Toledo
Mettler Toledo
Advertisement
PITTCON
PITTCON
Life Technologies